Shigemitsu Matsumoto

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Scohia Pharma, Inc.. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shigemitsu Matsumoto. Retrieved from https://idiyas.com/inventor/shigemitsu-matsumoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 75.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3

Average Co-Inventor Count = 8.4

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Tsukuba, JP (2013)
Kanagawa, JP (2014 - 2023)
Fujisawa, JP (2020 - 2024)

Company Filing History:

15 out of 1,226

Takeda Pharmaceutical Company Limited

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

2. 11713311 - Heterocyclic compound (2023-08-01),

3. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

4. 11518763 - Macrocyclic compound and use thereof (2022-12-06),

5. 11230541 - Heterocyclic compound (2022-01-25),

6. 10968231 - Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders (2021-04-06),

7. 10968213 - Cyclopropanamine compound and use thereof (2021-04-06),

8. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

9. 10414761 - Cyclopropanamine compound and use thereof (2019-09-17),

10. 10053456 - Cyclopropanamine compound and use thereof (2018-08-21),

11. 9920047 - Cyclopropanamine compound and use thereof (2018-03-20),

12. 9718814 - Cyclopropanamine compound and use thereof (2017-08-01),

13. 9714241 - Cyclopropanamine compound and use thereof (2017-07-25),

14. 9487511 - Cyclopropanamine compound and use thereof (2016-11-08),

15. 8772277 - Nitrogen-containing heterocyclic compound (2014-07-08),

Title: The Innovative Contributions of Shigemitsu Matsumoto

Introduction

Shigemitsu Matsumoto, an esteemed inventor based in Kanagawa, Japan, has made significant strides in the field of pharmacology. With a remarkable portfolio of 16 patents, Matsumoto's innovations primarily focus on the development of heterocyclic compounds that promise to revolutionize treatments for various mental health conditions.

Latest Patents

Matsumoto's latest patents feature groundbreaking heterocyclic compounds that demonstrate antagonistic effects on NMD A receptors, particularly those containing the NR2B subunit. These compounds are heralded as potential therapeutic agents for an array of conditions, including major depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia. Each compound is uniquely defined in the patent documents, representing a significant leap in the preventive and therapeutic capabilities for these debilitating disorders.

Career Highlights

Throughout his career, Shigemitsu Matsumoto has played an instrumental role in the pharmaceutical industry, particularly with recognized companies such as Takeda Pharmaceutical Company Limited and Scohia Pharma, Inc. His work has not only contributed to the advancement of drug development but also to the broader understanding of neuropharmacology.

Collaborations

Matsumoto has collaborated with prominent peers in his field, including Mitsuhiro Ito and Shinji Morimoto. These partnerships have been vital in driving innovative research forward, allowing for a multidisciplinary approach to tackle complex health challenges.

Conclusion

In conclusion, Shigemitsu Matsumoto's contributions to pharmacology through his innovative heterocyclic compounds mark him as a noteworthy inventor in the medical landscape. His patents are expected to leave a lasting impact on treatment strategies for mental health disorders, showcasing the crucial role that inventors play in advancing healthcare solutions.

Profile summary based on public USPTO records.